Analysis of correlation between heart failure in the early stage of acute myocardial infarction and serum pregnancy associated plasma protein-A, prealbumin, C-reactive protein, and brain natriuretic peptide levels

1. Adrenomedullin, a newly identified vasorelaxant peptide, participates in the regulation of the cardiovascular system. To investigate the pathophysiological significance of adrenomedullin in patients with acute myocardial infarction, we measured plasma levels of adrenomedullin. 2. Cardiac catheterization was performed on admission, after 1 day, and after 4 weeks in 36 patients with acute myocardial infarction. We measured plasma levels of adrenomedullin, atrial natriuretic peptide and brain natriuretic peptide in the right atrium, pulmonary artery and aorta. 3. Plasma levels of adrenomedullin in the right atrium (mean ± SEM) were significantly increased on admission (4.2 ± 2.6 h) in patients with acute myocardial infarction (10.6 ± 1.0 pmol/l) compared with controls (5.2 ± 0.3 pmol/l, P < 0.01). In addition, plasma levels of adrenomedullin were further elevated in patients with congestive heart failure (12.3 ± 1.4 pmol/l) compared with patients without congestive heart failure (7.8 ± 0.6 pmol/l, P < 0.01). In patients with congestive heart failure, plasma adrenomedullin on admission significantly correlated with atrial natriuretic peptide and brain natriuretic peptide. 4. These results suggest that plasma adrenomedullin increases in the early phase of acute myocardial infarction and that volume expansion may be one of the additional stimuli for the release of adrenomedullin in patients with acute myocardial infarction complicated by congestive heart failure.

Download Full-text

GW26-e4600 Clinical effect of recombinant human brain natriuretic peptide combined with levosimendan on acute myocardial infarction complicated with heart failure

Journal of the American College of Cardiology ◽

10.1016/j.jacc.2015.06.517 ◽

2015 ◽

Vol 66 (16) ◽

pp. C134

Author(s):

Zhenda Zheng ◽

Cailian Cheng ◽

Dinghui Liu ◽

Jianrui Zheng ◽

Zhiming Song ◽

...

Keyword(s):

Myocardial Infarction ◽

Heart Failure ◽

Acute Myocardial Infarction ◽

Human Brain ◽

Brain Natriuretic Peptide ◽

Natriuretic Peptide ◽

Clinical Effect

Download Full-text

553 Reduction of circulating levels of brain natriuretic peptide and C-reactive protein in patients with congestive heart failure after intermittent administration of levosimendan for 3 months

European Journal of Heart Failure Supplements ◽

10.1016/s1567-4215(06)80350-4 ◽

2006 ◽

Vol 5 (1) ◽

pp. 123-123

Author(s):

I VASSILIADIS ◽

S THOMOPOULOU ◽

S MAVROGENI ◽

E PAPADOPOULOU ◽

G GIAMOUZIS ◽

...

Keyword(s):

Heart Failure ◽

Congestive Heart Failure ◽

Brain Natriuretic Peptide ◽

Natriuretic Peptide ◽

C Reactive Protein ◽

Intermittent Administration ◽

Reactive Protein ◽

Circulating Levels

Download Full-text

Abstract 2370: LDL Independent Reduction In Cardiovascular Morbidity And Mortality With Rosuvastatin In Heart Failure Patients With A Raised C-reactive Protein: A Retrospective Analysis Of The Controlled Rosuvastatin Multinational Trial In Heart Failure (CORONA)

Circulation ◽

10.1161/circ.118.suppl_18.s_711-a ◽

2008 ◽

Vol 118 (suppl_18) ◽

Author(s):

John McMurray ◽

John Kjekshus ◽

Ake Hjalmarson ◽

Hans Wedel ◽

Peter Dunselman ◽

...

Keyword(s):

Myocardial Infarction ◽

Heart Failure ◽

Protein A ◽

Secondary Outcome ◽

C Reactive Protein ◽

Reactive Protein ◽

Cardiovascular Morbidity And Mortality ◽

Stable Coronary Heart Disease ◽

Anti Inflammatory ◽

Inflammatory Action

Objective: The anti-inflammatory action of statins may contribute to the clinical benefits of these drugs. Heart failure (HF) is an inflammatory state in which the usual epidemiologic relationship between cholesterol and cardiovascular outcomes is reversed, representing an excellent disease model in which to test the statin anti-inflammatory hypothesis. Methods: We carried out a retrospective subgroup analysis of CORONA, which randomized 5011 patients with low ejection fraction HF of ischemic etiology to placebo or rosuvastatin 10 mg daily. We examined the effect of rosuvastatin according to baseline plasma high-sensitivity C-reactive protein concentration (hs-CRP) with patients divided into two groups: < 2 mg/L (779 placebo/777 rosuvastatin) versus >/= 2 mg/L (1694 placebo/1711 rosuvastatin). Results (table ): Baseline LDL was the same in the two hsCRP groups (approx. 138 mg/dL) and was reduced equally by 45% in each group with rosuvastatin. In patients with a hsCRP >/= 2 mg/L, rosuvastatin treatment was associated with nominally statistically significant reductions in the primary outcome (cardiovascular death, myocardial infarction or stroke), all cause mortality and the pre-specified coronary endpoint (sudden death, fatal or nonfatal myocardial infarction, PCI or CABG, ventricular defibrillation by an ICD, resuscitation after cardiac arrest or hospitalization for unstable angina). Importantly, rosuvastatin also reduced the secondary outcome of HF hospitalizations: hsCRP < 2.0 mg/L 267 placebo/264 rosuvastatin (p n.s.); hsCRP >/= 2.0 mg/L 1015 placebo/827 rosuvastatin (p = 0.0044) Conclusions: Our findings in patients with HF support and extend previous retrospective analyses in patients with acute and stable coronary heart disease and add more evidence that the anti-inflammatory action of statins may be clinically important, not just in reducing atherosclerotic events but also HF hospitalizations.

Download Full-text